Combination therapy to treat moderate to severe psoriasis

Keyphrases

• Combination Therapy 100%
• Moderate-to-severe Psoriasis 100%
• Cyclosporine 66%
• Monotherapy 66%
• Phototherapy 66%
• Psoralen Plus Ultraviolet A 66%
• Adverse Effect Profile 66%
• Sequential Approach 66%
• Adverse Effects 33%
• Clinical Practice Guidelines 33%
• Severe Disease 33%
• Moderate to Severe 33%
• Remission 33%
• Biological Agents 33%
• Acute Toxicity 33%
• Evidence-based Treatment 33%
• Cancer Risk 33%
• Methotrexate 33%
• Loss of Effectiveness 33%
• New Biologics 33%
• Retinoids 33%
• Immunomodulator 33%
• Systemic Agents 33%
• Hydroxyurea 33%
• Ultraviolet-B (UV-B) 33%
• Combined Method 33%
• Synergistic Enhancement 33%
• Topical Agents 33%
• Cumulative Toxicity 33%
• Single-agent Therapy 33%
• Single Modality 33%
• Thioguanine 33%
• Vitamin D Derivatives 33%
• Acitretin 33%
• Long-term Maintenance 33%
• Action Effects 33%
• Novel Mode of Action 33%

Medicine and Dentistry

• Combination Therapy 100%
• Psoriasis 100%
• Adverse Event 66%
• Monotherapy 66%
• Cyclosporine 66%
• Psoralen 66%
• Health Care Cost 33%
• Phototherapy 33%
• Cancer Risk 33%
• Methotrexate 33%
• Immunomodulating Agent 33%
• Hydroxyurea 33%
• Retinoid 33%
• Topical Agent 33%
• Acute Toxicity 33%
• Vitamin D Derivative 33%
• Tioguanine 33%
• Etretin 33%
• Ultraviolet Phototherapy 33%
• Diseases 33%
• Adverse Effect 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Combination Therapy 100%
• Psoriasis 100%
• Adverse Event 66%
• Monotherapy 66%
• Ciclosporin 66%
• Psoralen 66%
• Remission 33%
• Methotrexate 33%
• Immunomodulating Agent 33%
• Hydroxycarbamide 33%
• Retinoid 33%
• Tioguanine 33%
• Topical Agent 33%
• Acute Toxicity 33%
• Vitamin D Derivative 33%
• Etretin 33%
• Diseases 33%